Terms: = Bone cancer AND CDK6, MGC59692, 1021, Q00534, ENSG00000105810, PLSTIRE AND Treatment
57 results:
1. Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM).
Mill CP; Fiskus WC; DiNardo CD; Reville P; Davis JA; Birdwell CE; Das K; Hou H; Takahashi K; Flores L; Ruan X; Su X; Loghavi S; Khoury JD; Bhalla KN
Blood Cancer J; 2024 Feb; 14(1):25. PubMed ID: 38316746
[TBL] [Abstract] [Full Text] [Related]
2. [Efficacy and safety of pegylated interferon alpha-2b for patients with myeloproliferative neoplasm].
Teng GS; Zhang YH; Wang Y; Du CX; Li YQ; Hu NB; Xiang GP; Shao ZH; Bai J
Zhonghua Yi Xue Za Zhi; 2023 Dec; 103(45):3645-3651. PubMed ID: 38018063
[No Abstract] [Full Text] [Related]
3. The Targeted Therapies for Osteosarcoma
Wang S; Ren Q; Li G; Zhao X; Zhao X; Zhang Z
Curr Mol Pharmacol; 2024; 17(1):e210823220109. PubMed ID: 37602543
[TBL] [Abstract] [Full Text] [Related]
4. Exosomal RNAs in the development and treatment of pituitary adenomas.
Chang M; Jiang S; Guo X; Gao J; Liu P; Bao X; Feng M; Wang R
Front Endocrinol (Lausanne); 2023; 14():1142494. PubMed ID: 36875488
[TBL] [Abstract] [Full Text] [Related]
5. BMP2 inhibits cell proliferation by downregulating EZH2 in gastric cancer.
Chen Z; Yuan L; Li X; Yu J; Xu Z
Cell Cycle; 2022 Nov; 21(21):2298-2308. PubMed ID: 35856444
[TBL] [Abstract] [Full Text] [Related]
6. Continuous treatment with abemaciclib leads to sustained and efficient inhibition of breast cancer cell proliferation.
Torres-Guzmán R; Ganado MP; Mur C; Marugan C; Baquero C; Yang Y; Zeng Y; Bian H; Du J; de Dios A; Puig O; Lallena MJ
Oncotarget; 2022; 13():864-875. PubMed ID: 35813283
[TBL] [Abstract] [Full Text] [Related]
7. Oncogenic lncRNA ZNFX1 antisense RNA 1 promotes osteosarcoma cells proliferation and metastasis by stabilizing serine and arginine‑rich splicing factor 3.
Zhang Y; Xu W; Wang Y; Li J; He G; Guan M; Zeng X; Bian W; Song Y; Liu J
Bioengineered; 2022 Mar; 13(3):5962-5974. PubMed ID: 35184675
[TBL] [Abstract] [Full Text] [Related]
8. Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial.
Fennell DA; King A; Mohammed S; Greystoke A; Anthony S; Poile C; Nusrat N; Scotland M; Bhundia V; Branson A; Brookes C; Darlison L; Dawson AG; Gaba A; Hutka M; Morgan B; Bajaj A; Richards C; Wells-Jordan P; Thomas A;
Lancet Oncol; 2022 Mar; 23(3):374-381. PubMed ID: 35157829
[TBL] [Abstract] [Full Text] [Related]
9. A murine mesenchymal stem cell model for initiating events in osteosarcomagenesis points to CDK4/cdk6 inhibition as a therapeutic target.
Franceschini N; Gaeta R; Krimpenfort P; Briaire-de Bruijn I; Kruisselbrink AB; Szuhai K; Palubeckaitė I; Cleton-Jansen AM; Bovée JVMG
Lab Invest; 2022 Apr; 102(4):391-400. PubMed ID: 34921235
[TBL] [Abstract] [Full Text] [Related]
10. Diagnostic value of
Nguyen A; Fullard K; Sheehan-Dare G; Tang R; Chan L; Ho B; Dear R; Keane J; Hickey A; Nandurkar R; Chen J; Chen A; Lim E; Emmett L
J Med Imaging Radiat Oncol; 2022 Sep; 66(6):731-737. PubMed ID: 34676675
[TBL] [Abstract] [Full Text] [Related]
11. Targeting the cdk6 Dependence of Ph+ Acute Lymphoblastic Leukemia.
Porazzi P; De Dominici M; Salvino J; Calabretta B
Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573335
[TBL] [Abstract] [Full Text] [Related]
12. Incidence and Severity of Myelosuppression With Palbociclib After Palliative bone Radiation in Advanced Breast cancer: A Single Center Experience and Review of Literature.
Norman H; Lee KT; Stearns V; Alcorn SR; Mangini NS
Clin Breast Cancer; 2022 Jan; 22(1):e65-e73. PubMed ID: 34419350
[TBL] [Abstract] [Full Text] [Related]
13. cdk6 Is a Therapeutic Target in Myelofibrosis.
Dutta A; Nath D; Yang Y; Le BT; Mohi G
Cancer Res; 2021 Aug; 81(16):4332-4345. PubMed ID: 34145036
[TBL] [Abstract] [Full Text] [Related]
14. Ankle osteonecrosis in fifty-one children and adolescent's leukemia survivors: a prospective randomized study on percutaneous mesenchymal stem cells treatment.
Hernigou P; Auregan JC; Dubory A; Flouzat Lachaniette CH; Rouard H
Int Orthop; 2021 Sep; 45(9):2383-2393. PubMed ID: 33893522
[TBL] [Abstract] [Full Text] [Related]
15. Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on
Silvestri G; Trotta R; Stramucci L; Ellis JJ; Harb JG; Neviani P; Wang S; Eisfeld AK; Walker CJ; Zhang B; Srutova K; Gambacorti-Passerini C; Pineda G; Jamieson CHM; Stagno F; Vigneri P; Nteliopoulos G; May PC; Reid AG; Garzon R; Roy DC; Moutuou MM; Guimond M; Hokland P; Deininger MW; Fitzgerald G; Harman C; Dazzi F; Milojkovic D; Apperley JF; Marcucci G; Qi J; Polakova KM; Zou Y; Fan X; Baer MR; Calabretta B; Perrotti D
Blood Cancer Discov; 2020 Jul; 1(1):48-67. PubMed ID: 32974613
[TBL] [Abstract] [Full Text] [Related]
16. microRNA-524-5p inhibits proliferation and induces cell cycle arrest of osteosarcoma cells via targeting cdk6.
Chen H; Cheng C; Gao S
Biochem Biophys Res Commun; 2020 Sep; 530(3):566-573. PubMed ID: 32747087
[TBL] [Abstract] [Full Text] [Related]
17. Antrodia cinnamomea is a potentially effective complementary medicine for adjuvant therapy against breast cancer with bone metastasis: A case report.
Long H; Hu CT; Prijatelj V; Weng CF
Medicine (Baltimore); 2020 Jul; 99(27):e20808. PubMed ID: 32629666
[TBL] [Abstract] [Full Text] [Related]
18. The Activity of Chemotherapy in Inflammatory Myofibroblastic Tumors: A Multicenter, European Retrospective Case Series Analysis.
Baldi GG; Brahmi M; Lo Vullo S; Cojocaru E; Mir O; Casanova M; Vincenzi B; De Pas TM; Grignani G; Pantaleo MA; Blay JY; Jones RL; Le Cesne A; Frezza AM; Gronchi A; Collini P; Dei Tos AP; Morosi C; Mariani L; Casali PG; Stacchiotti S
Oncologist; 2020 Nov; 25(11):e1777-e1784. PubMed ID: 32584482
[TBL] [Abstract] [Full Text] [Related]
19. Downregulated Long Non-Coding RNA MSC-AS1 Inhibits Osteosarcoma Progression and Increases Sensitivity to Cisplatin by Binding to MicroRNA-142.
Zhang L; Zhao G; Ji S; Yuan Q; Zhou H
Med Sci Monit; 2020 Mar; 26():e921594. PubMed ID: 32155139
[TBL] [Abstract] [Full Text] [Related]
20. Selective inhibition of Ph-positive ALL cell growth through kinase-dependent and -independent effects by cdk6-specific PROTACs.
De Dominici M; Porazzi P; Xiao Y; Chao A; Tang HY; Kumar G; Fortina P; Spinelli O; Rambaldi A; Peterson LF; Petruk S; Barletta C; Mazo A; Cingolani G; Salvino JM; Calabretta B
Blood; 2020 Apr; 135(18):1560-1573. PubMed ID: 32040545
[TBL] [Abstract] [Full Text] [Related]
[Next]
